Bioxytran Inc. Appoints Two Investment Bankers from Westbury Group to Its Advisory Board

September 16, 2019

BOSTON,MASSACHUSETTS, Sept. 16, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT),a developmental stage biotechnology company, focused on delivering a small moleculecarrying oxygen to the brains of stroke victims, announced today that it hasinvited John Jensen and Dr. Patrick Huddie from the Westbury Group to joinBioxytran’s Advisory Board to provide insight into capital markets, strategicpartnerships and licensing opportunities, particularly in relation to thecompany’s listing strategy.

John Jensenis a Managing Director of Westbury Group, an investment bank that focuses onbroad advisory and execution services for middle market companies. With morethan forty years of investment banking experience, Jensen spent thirty-twoyears at Merrill Lynch, retiring as the Vice Chairman of Global Equity CapitalMarkets.  In his career, he led the fund raising of more than $100 billionin equity offerings, including large, complex, global privatizations, such asFrance Telecom.  After retiring from Merrill Lynch, Jensen founded ahealthcare technology company, which was sold to a publicly held Belgiancompany in 2012.  Jensen graduated from the University of North Carolinaat Chapel Hill with a B.A. with Honors and he attended the New York University,Stern School of Business.

Dr. PatrickHuddie, a partner of Westbury Group, is an experienced investment banker withsubstantial experience in advising entrepreneurial ventures in the healthcaresector.  In the course of his career, he has advised many companiesregarding mergers and acquisitions, as well as debt and equityfinancings.  His clients have been primarily in the healthcare sector,including biotechnology, consumer goods, diagnostics and medical devices.Previously Huddie founded and operated an electro-optical engineering servicescompany that provided imaging and laser technology to federal governmentclients, as well as to biomedical research organizations and to themicroelectronics industry. The company successfully licensed and implementedNASA technology to create compact ultraviolet lasers for terrestrialapplications. 

Dr.Huddie's academic career included biophysical and pharmacological research andteaching at the National Institutes of Health, the Marine Biological Laboratoryin Massachusetts and the University of Rhode Island, as well as the Universityof Nottingham and the University of Newcastle-upon-Tyne in the United Kingdom.He holds an Honours degree in Physiology and a doctorate in Biophysics from theUniversity of Newcastle-upon-Tyne and he is a past member of the BiophysicalSociety, the Society of Photo-Optical Instrumentation Engineers and the Societyfor Neuroscience.

“Theaddition of these experienced investment bankers to our team strengthens ourfund-raising capability significantly”, stated Bioxytran CEO, David Platt. “Both have extensive experience and personal connections within theinvestment community. We were impressed by their in-depth knowledge, experienceand ability to communicate the value of Bioxytran’s platform technology, whichhas a myriad of potential applications treating a broad number of conditionssurrounding the delivery of oxygen to the brain.” 

“Weanticipate that Jensen and Huddie will be able to communicate the Bioxytranstory effectively.  Their expertise and experience in both investmentbanking and entrepreneurial ventures, in the healthcare sector in general andbiotechnology in particular, will assist Bioxytran in a number of areasincluding working with us to optimize the timing of our regulatoryinitiatives.  We are happy to welcome Jensen and Huddie to our AdvisoryBoard”, added Platt.  “We are excited to partner with Bioxytran and toassist the company in achieving its strategic, operating and financialobjectives”, said John Jensen.  “Bioxytran represents an opportunity toexploit many applications for its molecule that delivers oxygen to thebrain.  Bioxytran has the potential to create value by enhancing itsinvestor base through an understanding of the various applications thatBioxytran seeks to exploit with its molecule.”      

Huddiecommented “Bioxytran has the potential to help in stroke, as well as in otherneurodegenerative diseases where oxygen availability is a factor in diseaseprogression.  Hyperbaric chambers are used to treat a wide variety ofdiseases, but their potential is limited by the side effects of hyperoxia,which is essentially too much free oxygen in the patient’s tissues.  Moreover, adoption of hyperbaric therapy has been slowed by the scarcityand cost of chambers.  Bioxytran’s oxygen carrying drug, BXT-25, has thepotential to improve treatment and to enhance research in this area. Although BXT-25 has yet not entered clinical trials, the science behind thedrug lends itself to partnering and licensing, even at this early stage.”

Huddieadded: “Based upon my experience in the field of photo-optical instrumentation,Bioxytran’s MDX Viewer appears to have significant potential for use inoperating rooms globally.    We are pleased to be part of theBioxytran team and we hope to assist the company in achieving its strategicobjectives of enhancing shareholder value and partnering with other healthcareenterprises.”

About Bioxytran,Inc.

BioxytranInc. is a developmental stage biotechnology company.  The company isworking toward a first-in-class oxygen treatment platform for victims of brainstroke trauma.  The first product to proceed to testing is BXT-25, whichwill be evaluated as a resuscitative agent to treat strokes, especially duringthe all-critical first hour following a stroke.  The product will also beevaluated for its efficacy in treating other brain trauma issues.  BXT-25is based on a new molecule designed to reverse hypoxia in the brain.  Hypoxic brain injuries such as ischemic strokes, could be treated with BXT-25via an intravenous injection that quickly allows the drug molecule to travel tothe lungs and bind with the oxygen molecules.  From the lungs, the moleculemimics a red blood cell traveling to the brain.  Since the molecule is5,000 times smaller than red blood cells it can penetrate the clot and deliverthe oxygen to the critical areas in the brain blocked by the clot. To learnmore, visit our website:

Investor Relations
Resources Unlimited NW LLC